Patient and Caregiver Experiences with Huntington Disease: Emotions, Challenges, and Unmet Needs in the Patient Journey
Objective: To describe patients' emotional journey from symptom onset and diagnosis to current state and to identify challenges and unmet needs in Huntington disease (HD).…ECAP-Controlled Closed-Loop SCS Alleviates Neuropathic Pain and Improves Motor Function in a Patient Suffering from Parkinson’s Disease and Radicular Pain
Objective: The objective of this case report is to highlight the effect of a new technology, Evoked Compound Action Potential (ECAP) controlled closed-loop spinal cord…Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis
Objective: To compare the clinical effectiveness between continuous dopaminergic stimulation (CDS)-based and intermittent levodopa (IL) treatment in patients with early to mid-stage Parkinson’s disease (PD).…Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology
Objective: Levodopa-induced dyskinesias (LID) may be amenable to interventions with striatal serotonergic receptors. Preclinical evidence suggests that co-administration of serotonergic agonists with selective receptor properties…Faecal Microbiota Transplant for Parkinson’s Disease: a Phase 1 Pilot Study to Establish Safety and Tolerability
Objective: We performed a pilot study looking at the safety and tolerability of Faecal Microbiota Transplantation, its effect on the microbiome, and improvement of symptoms…Assessment of Motor and Non-Motor Alterations Impacting Functionality in Parkinson’s Disease Patients
Objective: To investigate the impact of motor and non-motor changes on the functionality of individuals with Parkinson's disease Background: Parkinson's disease (PD) is the second…Improvement in Upright Stability subscale of mFARS with Vatiquinone Treatment in MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial
Objective: Describe the results of vatiquinone on the Upright Stability Subscale (USS) from MOVE-FA (NCT04577352), the 72-week placebo-controlled phase 3 study of patients with Friedreich…eHealth Technologies for People with Parkinson’s: Acceptance & Implications
Objective: To investigate the impact of eHealth on Parkinson's care, focusing on technology acceptance and examining ethical, legal, social, and medical aspects of wearables. Background:…Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide
Objective: An innovative, multi-study Phase 3 program to definitively assess safety and efficacy of ulixacaltamide in essential tremor (ET). Background: Phase 2 studies of ulixacaltamide,…Safety and Efficacy of Vatiquinone Treatment in Friedreich Ataxia Patients from MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial
Objective: Describe the results of vatiquinone from MOVE-FA (NCT04577352), the 72-week placebo-controlled phase 3 study of patients with Friedreich Ataxia (FA). Background: FA, the most…
- « Previous Page
- 1
- …
- 318
- 319
- 320
- 321
- 322
- …
- 1734
- Next Page »